Advertisement

Document › Details
ProBioGen AG. (2/25/20). "Press Release: ImmunOs Therapeutics Selects ProBioGen for Development and Large-Scale Manufacturing Services". Berlin & Schlieren.
ProBioGen AG today announced that ImmunOs Therapeutics AG has signed a Manufacturing Services Agreement for their novel platform of multitasking biologics. ProBioGen will support ImmunOs in the development of their biologics using its recently launched DirectedLuck Transposase technology and conducting large scale GMP manufacturing.
ImmunOs has a pipeline of novel agents in development.
Dr. Wieland Wolf, CEO of ProBioGen: “We are pleased about this confidence in our expertise. It is our goal enabling ImmunOs to start clinical trials with this promising molecule in a timely manner. We are very passionate to develop a cell line and respective robust processes based on our innovative technologies to deliver their product with highest quality.“
No further details were disclosed.
About ProBioGen AG - www.probiogen.de
ProBioGen is a premier, Berlin-based specialist for developing and manufacturing of complex therapeutic antibodies and glycoproteins.
Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHTTM expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.
All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.
About ImmunOs Therapeutics AG - www.immunostherapeutics.com
ImmunOs Therapeutics AG is a biotechnology company active in the discovery and development of the next generation of novel human immunomodulatory proteins focused on innate immunity. Originally a spin-off company of the University of Zurich and the University of Basel, our mission is to develop novel therapeutics that will improve the lives of patients with serious disease.
ImmunOs Therapeutics AG lead program is a next generation, novel platform of multitasking biologics targeting diverse immunoregulatory receptors that activate anti-tumor responses built upon years of research and development. ImmunOs proteins work directly on the innate immune system. (For more information, please visit www.immunostherapeutics.com)
Contact ProBioGen AG
Dr Gabriele Schneider
Chief Business Officer
ProBioGen AG
Herbert-Bayer-Str. 8
13086 Berlin, Germany
Phone: +49 (0)30 3229 35 100
Email: cmo@probiogen.de
Website: www.probiogen.de
Contact ImmunOs Therapeutics AG
Investor Relations
Wagistrasse 14
8952 Schlieren (Zurich area), Switzerland
Email: info@immunostherapeutics.com
Record changed: 2020-04-01 |
Advertisement

More documents for Minapharm (Group)
- [1] ProBioGen AG. (10/22/20). "Press Release: Heidelberg Pharma Contracts ProBioGen for Cell Line Development and Manufacturing Services". Berlin....
- [2] ProBioGen AG. (4/28/20). "Press Release: ProBioGen AG Appoints Dr. Lutz Hilbrich as New Chief Executive Officer – Dr. Wieland Wolf Retires". Berlin & Cairo....
- [3] ProBioGen AG. (3/24/20). "Press Release: Immunogenesis Contracts ProBioGen for Development and Large-Scale Manufacturing Services". Berlin & Houston, TX....
- [4] ProBioGen AG. (1/14/20). "Press Release: ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule". Berlin & Utrecht....
- [5] ProBioGen AG. (1/8/20). "Press Release: ProBioGen Inks Next Commercial GlymaxX License with Roche. ADCC-enhancement for Innovative Cancer Therapy". Berlin....
- [6] ProBioGen AG. (11/12/19). "Press Release: DirectedLuck, a Transposase for Efficient Gene Delivery and High-Titer Cell Line Development". Berlin....
- [7] ProBioGen AG. (10/1/19). "Press Release: ProBioGen and Ceva Santé Animale Sign an Exclusive License Agreement to Produce Vectorised Poultry Vaccines Using AGE1.CR Production Technology". Berlin....
- [8] ProBioGen AG. (9/10/19). "Press Release: ProBioGen Licenses GlymaxX Technology to Bayer". Berlin....
- [9] ProBioGen AG. (5/15/19). "Press Release: ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform". Berlin & Oxford....
- [10] CRISPR Therapeutics AG. (1/22/19). "Press Release: CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies". Cambridge, MA, Boston, MA & Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
![Picture [iito] No Content Marketing 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-no-content-marketing.jpg)
» top